William Wierda, MD, PhD
Enriched profileProfessor of Medicine (Leukemia); Deputy Department Chair, Department of Leukemia; Executive Medical Director, Inpatient Medical Services; Section Chief, Chronic Lymphocytic Leukemia; Center Medical Director, Leukemia Center; Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey (2022–Present) · The University of Texas MD Anderson Cancer Center
William Wierda is Professor of Medicine (Leukemia); Deputy Department Chair, Department of Leukemia; Executive Medical Director, Inpatient Medical Services; Section Chief, Chronic Lymphocytic Leukemia; Center Medical Director, Leukemia Center; Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey (2022–Present) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,533 publications with 63,208 citations (h-index 122); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
William G. Wierda is Professor of Medicine (Leukemia) at The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Leukemia, Division of Cancer Medicine. The public record shows 1,533 publications with 63,208 citations (h-index 122), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 18 registered clinical trials, 2 NIH-funded awards (2009–2014).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Chronic Lymphocytic Leukemia Research
- 18 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 44 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 587.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Lilly USA, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
48.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor23.3%Valacyclovir100%Part D≥21 patientsFluoroquinolone Antibacterial14.2%Levofloxacin100%Part D≥13 patientsCancer & immunology
41.7%BCL-2 Inhibitor25.8%Venclexta100%Part D<11 patientsKinase inhibitor15.8%Calquence100%Part D<11 patientsMusculoskeletal
10%Xanthine oxidase inhibitor10%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2009–2014 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.
Journal of clinical oncology
Article2026 - Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
Blood advances
Clinical Trial2026 - Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.
Blood cancer discovery
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia2,249 citations2013
- 03Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors2,145 citations2020
- 04Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia1,887 citations2015
- 05Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia892 citations2015
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/william-wierda-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/william-wierda-77014510
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/william-wierda-b1915616
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
cllglobal.org/cll-global-research-foundation-president-dr-william-wierda
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cllglobal.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Faculty
Chronic Lymphocytic Leukemia Research Consortium (CRC), UC San Diego
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cll.ucsd.edu ↗
Media & interviews
press, podcasts and appearances- OncLive contributor/video series
recurring expert commentary on CLL treatment (BTK inhibitors, MRD-guided therapy, 17p deletion management)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Patient Power video interviews
CLL diagnostic workup, prognostic factors, and treatment options, with hosts Michele Nadeem-Baker and Jeff Folloder
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →patientpower.info ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center